MPN-CMML variant is enriched in active RAS/MAPK signaling, with ~70% of patients demonstrating RAS pathway mutations (e.g., NRAS, KRAS, CBL), with NRAS being the most commonly involved RAS-family gene. The gene discussed is KRAS; the disease is myeloproliferative neoplasm.